Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

Rivoceranib

Rivoceranib Phase 2

Elevar Therapeutics · Phase 2 · Terminated · Enrollment 80

NCT04119453

ArmReported safety
Rivoceranib 700 mggrade 3 or higher treatment-related adverse events: 70%, primary analysisdiscontinued for toxicity: 20%, primary analysis

A count stays a count. This page does not turn a count into a percent.